Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02412475
Title Epigenetic Reprogramming in Relapse AML
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michael Burke
Indications

acute myeloid leukemia

Therapies

Cytarabine

Sorafenib

Vorinostat

Filgrastim

Daunorubicin

Fludarabine

Decitabine

Age Groups: child | adult
Covered Countries USA


No variant requirements are available.